Kolitha Basnayake

Beware of Scam Calls

NUHS Institutions will NEVER ask you to transfer money or disclose bank details over a call.
If in doubt, call the 24/7 ScamShield helpline at 1799, or visit the ScamShield website at www.scamshield.gov.sg.

Doctor Details

2024/03/11

Dr Kolitha Basnayake

Designations:

Senior Consultant, Division of Renal Medicine, Department of Medicine, Ng Teng Fong General Hospital

Qualifications:

MBBS (London), MRCP (UK)

Specialties/Sub-specialties:

Renal Medicine

Special Interests:

Chronic kidney disease, Advanced kidney care, Haemodialysis, Kidney diseases associated with paraproteinaemias.

Locations:

Ng Teng Fong General Hospital

Make an Appointment

Contact Us:

Find Out More:

www.ntfgh.com.sg/Our-Services/Clinical-Services/Pages/Renal-Medicine.aspx

Make an Appointment

Biosketch

I completed my nephrology (renal medicine) training in the UK in 2011, and have held consultant level appointments at university hospitals in the UK. I have experience and expertise in the gamut of renal diseases and presentations. These include management of chronic kidney disease, chronic kidney disease with high risk of progression, advanced kidney care and preparation for end-stage kidney disease including dialysis and transplantation. I have a subspeciality interest in kidney diseases associated with paraproteinemia (such as multiple myeloma and monoclonal gammopathy of renal significance.

I have a PhD awarded by the University of Birmingham, where I investigated the role of immunoglobulin light chains in kidney disease. Alongside my clinical work, I have also undertaken research with a strong translational focus. I have been a Principal Investigator on numerous multicentre clinical trials, including non-commercial, commercial and interventional studies.

I have held a number of leadership roles in healthcare, delivering high quality care through a systems based approach to quality improvement.

Journals & Publications

1. Chronic kidney disease-associated pruritus (CKD-aP) is associated with worse quality of life and increased healthcare utilization among dialysis patients.

Titapiccolo JI, Lonati C, Goethel-Paal B, Bello AR, Bellocchio F, Pizzo A, Theodose M, Salvador MEB, Schofield M, Cioffi M, Basnayake K, Chisholm C, Mitrovic S, Trkulja M, Arens HJ, Stuard S, Neri L.

Qual Life Res. 2023 Oct;32(10):2939-2950.

2. Secretion of IL-1β From Monocytes in Gout Is Redox Independent.

Alberts BM, Bruce C, Basnayake K, Ghezzi P, Davies KA, Mullen LM.

Front Immunol. 2019 Jan 29;10:70.

3. A haemocompatible and scalable nanoporous adsorbent monolith synthesised using a novel lignin binder route to augment the adsorption of poorly removed uraemic toxins in haemodialysis.

Sandeman SR, Zheng Y, Ingavle GC, Howell CA, Mikhalovsky SV, Basnayake K, Boyd O, Davenport A, Beaton N, Davies N.

Biomed Mater. 2017 May 10;12(3):035001.

4. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.

Yadav P, Hutchison CA, Basnayake K, Stringer S, Jesky M, Fifer L, Snell K, Pinney J, Drayson MT, Cook M, Cockwell P.

Eur J Haematol. 2016 Jun;96(6):610-7.

5. The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.

Talbot B, Wright D, Basnayake K.

BMJ Case Rep. 2014 Oct 17;2014:bcr2014206688.

6. Serum polyclonal immunoglobulin free light chain levels predict mortality in people with chronic kidney disease.

Hutchison CA, Burmeister A, Harding SJ, Basnayake K, Church H, Jesky MD, White K, Green CE, Stringer SJ, Bassett P, Ferro CJ, Cockwell P.

Mayo Clin Proc. 2014 May;89(5):615-22.

7. An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis.

Sandeman SR, Howell CA, Phillips GJ, Zheng Y, Standen G, Pletzenauer R, Davenport A, Basnayake K, Boyd O, Holt S, Mikhalovsky SV.

J Mater Sci Mater Med. 2014 Jun;25(6):1589-97.

8. Recent advances in the pathogenesis and management of cast nephropathy (myeloma kidney).

Stringer S, Basnayake K, Hutchison C, Cockwell P.

Bone Marrow Res. 2011;2011:493697.

9. The biology of immunoglobulin free light chains and kidney injury.

Basnayake K, Stringer SJ, Hutchison CA, Cockwell P.

Kidney Int. 2011 Jun;79(12):1289-301.

10. Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

Ying WZ, Wang PX, Aaron KJ, Basnayake K, Sanders PW.

Blood. 2011 Jan 27;117(4):1301-7.

Professional Memberships

Royal College of Physicians, United Kingdom

2025/08/26